SecBot SecBot
SECBOTREPLAY Home › Report › TRVI

TRVI · Trevi Therapeutics announced an upcoming conference call to discuss its…

Trevi Therapeutics, Inc. · PRESS-RELEASE filed Mar 10, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Mar 10, 2026 at 16:05 ET

Trevi Therapeutics announced an upcoming conference call to discuss its fourth quarter and full-year 2025 financial results, along with business updates. No financial data was released in this press release, which serves only as a notification of the forthcoming earnings event.

  • Trevi Therapeutics will host a conference call on March 17, 2026, at 4:30 p.m. ET to discuss Q4 and full-year 2025 financial results.
  • The call will include senior management and will be webcast live; registration is required.
  • No financial results or material business updates were disclosed in this release.
  • The company is developing Haduvio™ (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough (RCC).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access